Navigation Links
deCODE Receives Nasdaq Bid Price Deficiency Notice
Date:9/17/2009

REYKJAVIK, Iceland, September 17 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that it has received a notice from the Nasdaq Stock Market indicating that deCODE is not in compliance with Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule") because the closing bid price per share for its common stock has been below $1.00 per share for 30 consecutive business days. In accordance with Nasdaq Listing Rules, deCODE will be provided 180 calendar days, or until March 15, 2010, to regain compliance with the Minimum Bid Price Rule. deCODE can achieve compliance if at any time before March 15, 2010, its common stock closes at $1.00 per share or more for at least 10 consecutive business days. This notification has no effect on the listing of deCODE's common stock at this time.

About deCODE

deCODE is a global leader in analysing and understanding the human genome. The company has identified key variations in the sequence of the genome conferring increased risk of major public health challenges from cardiovascular disease to cancer, and employs its gene discovery engine to develop DNA-based tests and scans to assess individual risk of common diseases; to license its tests and intellectual property to partners; and to provide comprehensive, leading- edge contract services to companies and research institutions around the globe. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com; at http://www.decodediagnostics.com; at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the effect of a potential delisting of our common stock from The Nasdaq Global Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contacts:

    deCODE genetics
    Joy Bessenger
    +1-212-481 3891
    ir@decode.is

    Edward Farmer
    +354-570-1900
    info@decode.is

    Gisli Arnason
    +354-570-1900
    info@decode.is



'/>"/>
SOURCE DeCODE Genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE genetics Announces Second Quarter 2009 Financial Results
2. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results
3. Its Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer
4. deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis
5. deCODE Reinstated to Nasdaq Global Market
6. deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
7. deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
8. deCODE genetics Announces First Quarter 2009 Financial Results
9. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
10. Nasdaq Stays Suspension of Trading in deCODE Stock
11. deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... 2017  Driven by consumers, preference towards more ... fastest growing categories, finds the recently published U.S. ... Care: Multi-regional Market Analysis and Opportunities study ... Kline. "Biotechnology actives are derived from ... effective for skin and hair care applications," explains ...
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
(Date:2/23/2017)... LONDON and NEW YORK ... at HIMSS, Lumeon , a leading digital ... (DN Telehealth), a provider of telemedicine and remote ... care pathways for telemedicine reimbursements.  ... and their patients, in real-time, extending consultations beyond ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):